H
Hiroaki Shimokawa
Researcher at Tohoku University
Publications - 976
Citations - 56856
Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.
Papers
More filters
Journal ArticleDOI
Postprandial increase in plasma concentrations of remnant-like particles: an independent risk factor for restenosis after percutaneous coronary intervention.
Keiji Oi,Hiroaki Shimokawa,Yoji Hirakawa,Hideki Tashiro,Ryuichi Nakaike,Toshiyuki Kozai,Keizaburo Ohzono,Kunihiko Yamamoto,Samon Koyanagi,Shuichi Okamatsu,Tsukasa Tajimi,Yutaka Kikuchi,Akira Takeshita +12 more
TL;DR: It is indicated that post-prandial increase in RLP-C concentrations is an independent risk factor for restenosis after successful PCI, even in patients with normal fasting R LP-C levels.
Journal ArticleDOI
Heterogeneity of endothelium-dependent and endothelium-independent responses to aggregating platelets in porcine pulmonary arteries.
TL;DR: In large and small porcine pulmonary arteries, serotonin and ADP are the major contributors to the endothelium-dependent relaxation caused by aggregating platelets, while histamine appears to be responsible for the contraction that platelets cause in rings without endothelia.
Journal ArticleDOI
Development of polymeric drug delivery system for recognizing vascular endothelial dysfunction
Kenjiro Ikuta,Takeshi Mori,Tatsurhiro Yamamoto,Takuro Niidome,Hiroaki Shimokawa,Yoshiki Katayama +5 more
TL;DR: A polymeric drug carrier bearing an Evans blue analogue as a probing unit for endothelium injury and spontaneously formed stable nanoparticles with micelle-like structure in aqueous media and could encapsulate hydrophobic doxorubicin (DOX).
Journal ArticleDOI
Low-energy extracorporeal shock wave therapy for a model of liver cirrhosis ameliorates liver fibrosis and liver function.
Naoto Ujiie,Toru Nakano,Toru Nakano,Masato Yamada,Chiaki Sato,Chikashi Nakanishi,Fumiyoshi Fujishima,Kenta Ito,Tomohiko Shindo,Hiroaki Shimokawa,Takashi Kamei +10 more
TL;DR: Low-energy extracorporeal shock waves therapy is suggested to ameliorate liver fibrosis by reducing the expression of TGF-β1 and increasing theexpression of angiogenic factors, and improves hepatic function.
Journal ArticleDOI
Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease
Haruka Sato,Koichiro Sugimura,Masanobu Miura,Ryo Konno,Katsuya Kozu,Nobuhiro Yaoita,Toru Shimizu,Saori Yamamoto,Tatsuo Aoki,Shunsuke Tatebe,Kimio Satoh,Hiroaki Shimokawa +11 more
TL;DR: A patient with suspected PVOD who has been successfully treated with imatinib and is alive for 6 years after diagnosis is reported, suggesting that imatinIB may be a treatment option for PVOD and a bridge to lung transplantation.